Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.64
WMGI's Cash to Debt is ranked higher than
51% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. WMGI: 0.64 )
WMGI' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 0.64

Equity to Asset 0.46
WMGI's Equity to Asset is ranked higher than
51% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. WMGI: 0.46 )
WMGI' s 10-Year Equity to Asset Range
Min: -1.02   Max: 0.82
Current: 0.46

-1.02
0.82
F-Score: 2
Z-Score: 1.29
M-Score: -3.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -116.46
WMGI's Operating margin (%) is ranked lower than
55% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. WMGI: -116.46 )
WMGI' s 10-Year Operating margin (%) Range
Min: -116.46   Max: 13.22
Current: -116.46

-116.46
13.22
Net-margin (%) -113.05
WMGI's Net-margin (%) is ranked lower than
54% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. WMGI: -113.05 )
WMGI' s 10-Year Net-margin (%) Range
Min: -113.05   Max: 12.48
Current: -113.05

-113.05
12.48
ROE (%) -59.59
WMGI's ROE (%) is ranked lower than
56% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. WMGI: -59.59 )
WMGI' s 10-Year ROE (%) Range
Min: -59.59   Max: 12.22
Current: -59.59

-59.59
12.22
ROA (%) -27.19
WMGI's ROA (%) is ranked lower than
52% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. WMGI: -27.19 )
WMGI' s 10-Year ROA (%) Range
Min: -27.19   Max: 9.07
Current: -27.19

-27.19
9.07
ROC (Joel Greenblatt) (%) -98.97
WMGI's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. WMGI: -98.97 )
WMGI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -98.97   Max: 21.04
Current: -98.97

-98.97
21.04
Revenue Growth (%) -26.90
WMGI's Revenue Growth (%) is ranked lower than
52% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. WMGI: -26.90 )
WMGI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 14.8
Current: -26.9

0
14.8
» WMGI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

WMGI Guru Trades in Q1 2013

Jim Simons 256,527 sh (New)
John Keeley 1,222,950 sh (+11.69%)
Mario Gabelli 211,000 sh (unchged)
Ken Fisher 2,467,229 sh (-0.69%)
Paul Tudor Jones 100,000 sh (-13.12%)
Michael Price 405,758 sh (-18.85%)
Steven Cohen 365,859 sh (-21.51%)
Joel Greenblatt 29,615 sh (-34.43%)
» More
Q2 2013

WMGI Guru Trades in Q2 2013

Steven Cohen 411,054 sh (+12.35%)
John Keeley 1,248,520 sh (+2.09%)
Ken Fisher 2,494,454 sh (+1.1%)
Mario Gabelli 211,000 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Michael Price 210,000 sh (-48.25%)
Jim Simons 67,727 sh (-73.6%)
» More
Q3 2013

WMGI Guru Trades in Q3 2013

Paul Tudor Jones 400,000 sh (New)
Steven Cohen 1,009,800 sh (+145.66%)
John Keeley 1,345,690 sh (+7.78%)
Mario Gabelli 211,000 sh (unchged)
Ken Fisher 2,488,884 sh (-0.22%)
Michael Price 94,518 sh (-54.99%)
Jim Simons 16,731 sh (-75.3%)
» More
Q4 2013

WMGI Guru Trades in Q4 2013

Michael Price 774,852 sh (+719.79%)
John Keeley 1,412,920 sh (+5%)
Jim Simons 16,731 sh (unchged)
Mario Gabelli 211,000 sh (unchged)
Ken Fisher 2,469,109 sh (-0.79%)
Steven Cohen 934,520 sh (-7.45%)
Paul Tudor Jones 231,778 sh (-42.06%)
» More
» Details

Insider Trades

Latest Guru Trades with WMGI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Michael Price 2013-12-31 Add 719.79%0.18%$26.42 - $30.49 $ 28.420%774852
Michael Price 2013-09-30 Reduce -54.99%0.41%$23.85 - $28.22 $ 28.429%94518
Michael Price 2013-06-30 Reduce -48.25%0.63%$22.71 - $26.21 $ 28.4217%210000
Joel Greenblatt 2013-06-30 Sold Out 0.04%$22.71 - $26.21 $ 28.4217%0
Joel Greenblatt 2013-03-31 Reduce -34.43%0.02%$20.83 - $24.37 $ 28.4227%29615
Joel Greenblatt 2012-12-31 New Buy0.06%$19.67 - $22.19 $ 28.4236%45167
Joel Greenblatt 2012-09-30 Sold Out 0.05%$18.25 - $22.47 $ 28.4239%0
Joel Greenblatt 2012-06-30 Add 106.38%0.03%$18.02 - $21.21 $ 28.4244%34444
Joel Greenblatt 2012-03-31 New Buy0.03%$16.06 - $19.56 $ 28.4275%16690
Michael Price 2011-12-31 Add 25.96%0.35%$13.58 - $18.33 $ 28.4277%655000
John Keeley 2011-12-31 Add 1433.33%0.24%$13.58 - $18.33 $ 28.4277%766663
John Keeley 2011-09-30 New Buy0.02%$13.56 - $18.3 $ 28.4284%50000
George Soros 2011-09-30 Sold Out 0.0022%$13.56 - $18.3 $ 28.4284%0
Michael Price 2011-06-30 New Buy1.27%$14.23 - $17.14 $ 28.4285%581518
Mario Gabelli 2011-06-30 Add 282%0.02%$14.23 - $17.14 $ 28.4285%191000
George Soros 2011-06-30 Reduce -39.64%$14.23 - $17.14 $ 28.4285%10200
PRIMECAP Management 2011-06-30 Sold Out $14.23 - $17.14 $ 28.4285%0
Mario Gabelli 2011-03-31 Reduce -63.77%0.02%$14.5 - $17.41 $ 28.4278%50000
PRIMECAP Management 2011-03-31 Add 74.76%0.02%$14.5 - $17.41 $ 28.4278%2106328
George Soros 2011-03-31 New Buy$14.5 - $17.41 $ 28.4278%16900
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.90
WMGI's P/B is ranked higher than
61% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. WMGI: 2.90 )
WMGI' s 10-Year P/B Range
Min: 1.09   Max: 4.8
Current: 2.9

1.09
4.8
P/S 5.30
WMGI's P/S is ranked lower than
68% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. WMGI: 5.30 )
WMGI' s 10-Year P/S Range
Min: 0.96   Max: 5.3
Current: 5.3

0.96
5.3
EV-to-EBIT 200.00
WMGI's EV-to-EBIT is ranked lower than
76% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. WMGI: 200.00 )
WMGI' s 10-Year EV-to-EBIT Range
Min: 11.2   Max: 763.6
Current: 200

11.2
763.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.40
WMGI's Price/Tangible Book is ranked higher than
55% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. WMGI: 4.40 )
WMGI' s 10-Year Price/Tangible Book Range
Min: 1.52   Max: 6.07
Current: 4.4

1.52
6.07
Price/DCF (Projected) 4.20
WMGI's Price/DCF (Projected) is ranked lower than
68% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. WMGI: 4.20 )
WMGI' s 10-Year Price/DCF (Projected) Range
Min: 1.79   Max: 4.57
Current: 4.2

1.79
4.57
Price/Median PS Value 1.70
WMGI's Price/Median PS Value is ranked lower than
69% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. WMGI: 1.70 )
WMGI' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 1.84
Current: 1.7

0.47
1.84
Earnings Yield (Greenblatt) 0.50
WMGI's Earnings Yield (Greenblatt) is ranked lower than
65% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. WMGI: 0.50 )
WMGI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.9
Current: 0.5

0.1
8.9
Forward Rate of Return (Yacktman) 0.48
WMGI's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. WMGI: 0.48 )
WMGI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.8   Max: 18
Current: 0.48

-13.8
18

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:WM3.Germany
Wright Medical Group, Inc. is a Delaware Corporation. The Company through Wright Medical Technology, Inc. (WMT) and other operating subsidiaries (Wright), is a global orthopaedic medical device company specializing in the design, manufacture and marketing of devices and biologic products for extremity, hip and knee repair and reconstruction. It is a provider of surgical solutions for the foot and ankle market. Reconstructive devices are used to replace or repair knee, hip and other joints and bones that have deteriorated or have been damaged through disease or injury. Biologics are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and their patients. Within these markets, it focuses on the higher-growth sectors of the orthopaedic industry, such as the foot and ankle market, as well as on the integration of its biologic products into reconstructive procedures and other orthopaedic applications. Foot and ankle reconstruction includes implants and other devices to replace or reconstruct injured or diseased joints and bones in the foot and ankle. The Company's biologic products are primarily used in extremity-related procedures as well as in trauma and tumor induced voids of the long bones, joint replacements and some spine procedures. Biologic products provide a lower morbidity solution to 'autografting,' a procedure that involves harvesting a patient's own bone or soft tissue and transplanting it to a different site. The Company's flagship, PRO-DENSE injectable regenerative graft is an osteoconductive bone graft which provides the benefits of injectability, hardness to support bone and predictable bone regeneration. Soft tissue repair products, such as its GRAFTJACKET regenerative tissue matrix, enable the repair of soft tissue such as tendons (e.g., rotator cuff and Achilles), ligaments or chronic wounds such as diabetic foot ulcers. The Company's products are strictly regulated by the FDA under the Food, Drug, and Cosmetic Act (FDC Act). Some of its products are also regulated by state agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide